The recently completed SOUL trial further elucidated the CV benefits of oral semaglutide, addressing the limitations observed in the earlier PIONEER-6 trial, where a reduction in MACE did not reach statistical significance ( 55 ).
1
—
—
The recently completed SOUL trial further elucidated the CV benefits of oral semaglutide, addressing the limitations observed in the earlier PIONEER-6 trial, where a reduction in MACE did not reach statistical significance ( 55 ).